NCT01146678View on ClinicalTrials.gov

Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

January 31, 2011

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Insulin glargine HOE901

"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"

DRUG

Lixisenatide AVE0010

"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Berlin

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY